9 Drug Companies Agree to Lower U.S. Medicine Prices

Americans may soon pay less for their medications thanks to new pricing agreements with nine pharmaceutical companies announced this week.

The companies include Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB. They join 17 other drugmakers who made similar commitments earlier this year, bringing the total to 26 companies working to make medicines more affordable.

Under the deals, these companies agreed to sell new medications to U.S. patients at prices comparable to what people pay in other developed countries. They'll also offer their drugs to state Medicaid programs at "most-favored nation" prices, meaning the lowest rates available anywhere.

The agreements go beyond just pricing. Four of the companies will contribute 290 metric tons of active pharmaceutical ingredients to America's strategic medical reserves. Several companies also committed to strengthening domestic drug manufacturing, reducing reliance on overseas production.

The Ripple Effect

These deals could reshape how Americans access essential medications. For years, U.S. patients have paid significantly more than people in other wealthy nations for the same drugs, sometimes two to three times as much.

The impact extends beyond individual wallets. State Medicaid programs serving millions of low-income Americans will see reduced costs, potentially freeing up resources for other healthcare needs. Strengthening domestic manufacturing also means greater security during health emergencies when supply chains get disrupted.

With 26 companies now participating, the agreements cover a growing portion of medications available to Americans. Each new company that signs on expands the reach of more affordable pricing to more patients across the country.

The deals represent a shift toward pricing transparency and fairness in the pharmaceutical industry. Patients who once faced impossible choices between medications and other necessities may find relief as more companies join the effort.

More than two dozen major drug companies are now committed to making medicines accessible at fair prices for all Americans.